Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Ann Arbor Stage I Diffuse Large B-Cell Lymphoma: early-phase trial registry

1 of 1 indexed Ann Arbor Stage I Diffuse Large B-Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Ann Arbor Stage I Diffuse Large B-Cell Lymphoma: 1 US clinical trial tracked, 1 recruiting.

Ann Arbor Stage I Diffuse Large B-Cell Lymphoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is AIDS Malignancy Consortium, running 1 of these trials.

Enrollment posture brief

Registry condition ann-arbor-stage-i-diffuse-large-b-cell-lymphoma

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Ann Arbor Stage I Diffus (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Ann Arbor Stage I Diffuse Large B-Cell Lymphoma

Ann Arbor Stage I Diffuse Large B-Cell Lymphoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ann Arbor Stage I Diffuse Large B-Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ann Arbor Stage I Diffuse Large B-Cell Lymphoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Ann Arbor Stage I Diffuse Large B-Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Daratumumab Biological
1 trials
Etoposide Drug
1 trials
Doxorubicin Hydrochloride Drug
1 trials
Doxorubicin Drug
1 trials
Cyclophosphamide Drug
1 trials

US sites by state

Facility locations filed on Ann Arbor Stage I Diffuse Large B-Cell Lymphoma trials. A trial with sites in several states counts in each.

Texas 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Maryland 1 trials
Illinois 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ann Arbor Stage I Diffuse Large B-Cell Lymphoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Ann Arbor Stage I Diffuse Large B-Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • AIDS Malignancy Consortium sponsors the most Ann Arbor Stage I Diffuse Large B-Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See AIDS Malignancy Consortium's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ann Arbor Stage I Diffuse Large B-Cell Lymphoma condition card totals 1 registered trials; most-linked intervention Daratumumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.